

CHEMOCENTRYX, INC.

Reported by
BEKKER PETRUS

FORM 4

(Statement of Changes in Beneficial Ownership)

Filed 06/30/17 for the Period Ending 06/28/17

Address	850 MAUDE AVENUE MOUNTAIN VIEW, CA 94043
Telephone	650-210-2900
CIK	0001340652
Symbol	CCXI
SIC Code	2834 - Pharmaceutical Preparations
Industry	Pharmaceuticals
Sector	Healthcare
Fiscal Year	12/31

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

[] Check this box if no longer
subject to Section 16. Form 4 or
Form 5 obligations may
continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or
Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person *			2. Issuer Name and Ticker or Trading Symbol			5. Relationship of Reporting Person(s) to Issuer (Check all applicable)		
Bekker Petrus			ChemoCentryx, Inc. [CCXI]			<input type="checkbox"/> Director <input type="checkbox"/> 10% Owner <input checked="" type="checkbox"/> X Officer (give title below) <input type="checkbox"/> Other (specify below) Chief Medical Officer		
(Last) (First) (Middle)			3. Date of Earliest Transaction (MM/DD/YYYY)					
C/O CHEMOCENTRYX, INC., 850 MAUDE AVENUE			6/28/2017					
(Street)			4. If Amendment, Date Original Filed (MM/DD/YYYY)			6. Individual or Joint/Group Filing (Check Applicable Line)		
MOUNTAIN VIEW, CA 94043						<input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person		
(City) (State) (Zip)								

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	6/28/2017		M		30000	A	\$7.10	89839	D	
Common Stock	6/28/2017		S (1)		30000	D	\$9.1223 (2)	59839	D	
Common Stock	6/29/2017		M		5509	A	\$7.10	65348	D	
Common Stock	6/29/2017		S (1)		5509	D	\$9.1064 (2)	59839	D	
Common Stock	6/30/2017		M		11991	A	\$7.10	71830	D	
Common Stock	6/30/2017		S (1)		11991	D	\$9.1224 (3)	59839	D	
Common Stock	6/30/2017		M		18009	A	\$6.30	77848	D	
Common Stock	6/30/2017		S (1)		18009	D	\$9.30	59839	D	

Table II - Derivative Securities Beneficially Owned (e.g. , puts, calls, warrants, options, convertible securities)

1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option (right to buy)	\$7.10	6/28/2017		M		30000		(4)	2/19/2024	Common Stock	30000	(5)	160000	D	
Stock Option (right to buy)	\$7.10	6/29/2017		M		5509		(4)	2/19/2024	Common Stock	5509	(5)	154491	D	
Stock Option (right to buy)	\$7.10	6/30/2017		M		11991		(4)	2/19/2024	Common Stock	11991	(5)	142500	D	
Stock Option (right to buy)	\$6.30	6/30/2017		M		18009		(4)	8/10/2020	Common Stock	18009	(5)	29751	D	

Explanation of Responses:

- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
- Reflects the weighted average sale price of the shares sold. The shares were sold in multiple trades at prices ranging from \$9.10 to \$9.16 per share, inclusive. The Reporting Person will provide to the SEC staff, the issuer or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price.
- Reflects the weighted average sale price of the shares sold. The shares were sold in multiple trades at prices ranging from \$9.10 to \$9.20 per share, inclusive. The Reporting Person will provide to the SEC staff, the issuer or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price.
- As of June 28, 2017, and prior to this transaction, the exercised options were fully vested.
- Not applicable.

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Bekker Petrus C/O CHEMOCENTRYX, INC. 850 MAUDE AVENUE MOUNTAIN VIEW, CA 94043			Chief Medical Officer	

Signatures

/s/ Susan M. Kanaya, as Attorney-in-Fact

6/30/2017

**Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.